EP 212: A hub-and-spoke model for accelerating rare disease drug development with Ananth Sridhar and Sun-Gou Ji of BridgeBio

<p><strong>Summary: </strong></p><p>This week on The Genetics Podcast, Patrick is joined by BridgeBio’s Ananth Sridhar, Chief Operating Officer of Cardiorenal Programs, and Sun-Gou Ji, Vice President of Computational Genomics. They discuss the hub-and-spoke model for de-risking and accelerating rare disease drug development, the role of human genetics in target discovery, lessons from their autosomal dominant hypocalcemia type 1 (ADH1) program, and how portfolio design and predictive genomics are shaping the future of precision medicine.</p><p><br></p><p><strong>Show Notes: </strong></p><p><strong>0:00 </strong>Intro to The Genetics Podcast</p><p><strong>00:59</strong> Welcome to Ananth &amp; Sun-Gou</p><p><strong>01:57</strong> How BridgeBio’s hub-and-spoke model de-risks and accelerates rare disease drug development</p><p><strong>06:45 </strong>How programs move from the hub to the spokes in target discovery and development</p><p><strong>09:10</strong> Translating a target into a the...